key: cord-0743255-tszbhc9v authors: Hariyanto, Timotius Ivan; Halim, Devina Adella; Jodhinata, Claudia; Yanto, Theo Audi; Kurniawan, Andree title: Colchicine treatment can improve outcomes of coronavirus disease 2019 (COVID‐19): A systematic review and meta‐analysis date: 2021-03-14 journal: Clin Exp Pharmacol Physiol DOI: 10.1111/1440-1681.13488 sha: 24817068f0bb7df0684380add9f16f647ffb4400 doc_id: 743255 cord_uid: tszbhc9v Currently, there is no widely acceptable and proven effective treatment for coronavirus disease 2019 (COVID‐19). Colchicine has been shown to offer a benefit in reducing the inflammation in several inflammatory diseases. This study aims to analyze the efficacy of colchicine administration and outcomes of COVID‐19. We systematically searched the PubMed and Europe PMC database using specific keywords related to our aims until January 29, 2021. All articles published on COVID‐19 and colchicine treatment were retrieved. The quality of the study was assessed using the Newcastle–Ottawa Scale (NOS) tool for observational studies and Revised Cochrane risk‐of‐bias tool for randomized trials (RoB 2) for clinical trial studies. Statistical analysis was done using Review Manager 5.4 software. A total of eight studies with 5778 COVID‐19 patients were included in this meta‐analysis. This meta‐analysis showed that the administration of colchicine was associated with improvement of outcomes of COVID‐19 [OR 0.43 (95% CI 0.34–0.55), p < 0.00001, I (2) = 0%, fixed‐effect modelling] and its subgroup which comprised of reduction from severe COVID‐19 [OR 0.44 (95% CI 0.31–0.63), p < 0.00001, I (2) = 0%, fixed‐effect modelling] and reduction of mortality rate from COVID‐19 [OR 0.43 (95% CI 0.32–0.58), p < 0.00001, I (2) = 0%, fixed‐effect modelling]. Our study suggests the routine use of colchicine for treatment modalities of COVID‐19 patients. More randomized clinical trial studies are still needed to confirm the results from this study. In December 2019, the first cases of an acute respiratory illness (now known as the coronavirus disease 2019 or COVID- 19) were first reported in Wuhan, China. As of December 22, 2020, a total of about 75.1 million cases and 1 680 794 deaths have been identified across the world. 1 This disease can have a wide variety of clinical manifestations, from mild respiratory symptoms such as fever, cough, and anosmia to severe-life threatening conditions such as respiratory distress, arrhythmia, sepsis, shock, and loss of consciousness. 2 The pathophysiology of severe COVID-19 involves hyperinflammatory response and excessive production of pro-inflammatory cytokines such as interleukin-1β (IL-1β), interleukin-6 (IL-6), and tumour necrosisα (TNFα), which is commonly called a cytokine storm. 3, 4 Meta-analysis studies have identified several comorbidities that were associated with severe outcomes and mortality from COVID-19, such as hypertension, diabetes, thyroid disease, dyslipidaemia, dementia, cardiovascular disease, and pulmonary disease. [5] [6] [7] [8] [9] Therefore, efforts have been made to reduce the severity and mortality of COVID-19, including searching for a potential therapy. So far, there are no medications which have been proven effective for COVID-19. Previously suggested agents like hydroxychloroquine, lopinavir-ritonavir, remdesivir, and tocilizumab did not show promising results to the outcomes of COVID-19. 10 Based on the aforementioned pathophysiologic process of COVID-19, several experts have recommended the use of colchicine as treatment for COVID-19. Colchicine is a drug that is commonly used to treat and prevent the acute gout attacks, other crystal arthropathies, Familial Mediterranean Fever (FMF), and systemic vasculitis such as Behcet disease. Colchicine has anti-inflammatory properties which may be beneficial in alleviating the cytokine storm through its action on NLRP3 and inhibition of IL-1β, IL-6, and IL-18 activation. 11 However, the evidence regarding the association between colchicine use and COVID-19 is still unclear. This article aims to explore the potential association between treatment with colchicine and outcomes of COVID-19. Studies were included in this review if they met the following inclusion criteria: representation for clinical questions (P, positive/confirmed cases of COVID-19; I, a group who receive colchicine as their medications; C, a group of patients who did not receive colchicine as their medication and only receive standard of care treatment or receive other medications besides colchicine; O, COVID-19 outcomes which comprised of severe COVID-19 and mortality from COVID-19), type of study was a randomized control trial, cohort, clinical trial, case-cohort, and cross-over design, and if the full-text article was available. The following types of articles were excluded: articles other than original research (e.g., review articles, letters, or commentaries); case reports; articles not in the English language; articles on research in paediatric populations (17 years of age or younger); and articles on research in pregnant women. Brunetti L et al. 14 Data extraction was performed independently by two authors, we used standardized forms that include author, year, study design, number of participants, age, gender, colchicine dosage, time to colchicine administration, and proportion of patients in each groups of treatment. The Two investigators independently evaluated the quality of the included cohort and case-control studies using the Newcastle-Ottawa Scale (NOS). 12 The selection, comparability, and exposure of each study were broadly assessed and studies were assigned a score from zero to nine. Studies with scores ≥7 were considered of good quality. They also independently evaluated the quality of the included clinical trial studies using the Revised Cochrane risk-of-bias tool for randomized trials (RoB 2). 13 A meta-analysis was performed using Review Manager 5.4 (Cochrane Collaboration) software. We used the Generic Inverse Variance formula with fixed-effects models to calculate each outcome's risk. The heterogeneity was assessed by using the I 2 statistic with a value of <25%, 26-50%, and >50% were considered as low, moderate, and high degrees of heterogeneity, respectively. The effect estimate was reported as odds ratio (OR) along with its 95% confidence intervals (CIs) for dichotomous variables, respectively. The p-value was two-tailed, and the statistical significance was set at ≤0.05. We performed Begg's funnel-plot analysis to qualitatively assess the risk of publication bias. were excluded because the articles were not in English, and finally, eight studies 14-21 with a total of 5778 COVID-19 patients and 2668 patients who receive colchicine treatment were included in the metaanalysis (Figure 1 ). Of a total of eight included studies, three studies were a randomized clinical trial study, two studies were retrospective cohort, two studies were prospective cohort, and the remaining one study was a case-control study. The essential characteristics of the included studies are summarized in Table 1 . Studies with various study designs including cohort and casecontrol were included in this review and assessed accordingly with the appropriate scale or tool. Newcastle-Ottawa Scales (NOS) were used to assess the cohort and case-control studies ( Table 2) . All included studies were rated "good". For clinical trial studies, the Revised Cochrane risk-of-bias tool for randomized trials (RoB 2) was used and all of the included trials showed a low risk of bias (Table 3 ). In conclusion, all studies were seemed fit to be included in the meta-analysis. Our pooled analysis showed that administration of colchicine was as- (Figure 2 ). The funnel-plot analysis showed a qualitatively symmetrical in- 24 Coronaviruses, including SARS-CoV-2, are also dependent on microtubule-associated transport for their replication process. yet. Second, we include some pre-print studies to minimize the risk of publication bias; however, the authors have made exhaustive efforts to ensure that only sound studies were included and we expect that most of those studies currently available in pre-print form will eventually be published and that we will identify them through ongoing electronic literature surveillances. We hope that this study can give further insight into the treatment in COVID-19 patients. Colchicine administration can reduce the severity and mortality rate in COVID-19 patients. Hence, physicians may consider adding/giving colchicine as a treatment for patients with COVID-19 to help in preventing the severe outcome and mortality of the disease. More randomized clinical trial of colchicine is still needed to give a better assessment of colchicine efficacy. Finally, colchicine shall be regarded as an important agent in future treatment models for COVID-19. None. None. The data that support the findings of this study are openly available in PubMed at https://pubmed.ncbi.nlm.nih.gov/, reference number 14-21. Andree Kurniawan https://orcid.org/0000-0002-5219-9029 World Health Organization. Coronavirus disease (COVID-19): situation report Anosmia/Hyposmia is a good predictor of coronavirus disease 2019 (COVID-19) infection: a meta-analysis Tocilizumab administration is associated with the reduction in biomarkers of coronavirus disease 2019 infection Inflammatory and hematologic markers as predictors of severe outcomes in COVID-19 infection: a systematic review and meta-analysis Thyroid disease is associated with severe coronavirus disease 2019 (COVID-19) infection Anemia is associated with severe coronavirus disease 2019 (COVID-19) infection Dementia and outcomes from coronavirus disease 2019 (COVID-19) pneumonia: a systematic review and meta-analysis Dementia is a predictor for mortality outcome from coronavirus disease 2019 (COVID-19) infection. Eur Arch Psychiatry Clin Neurosci Statin therapy did not improve the inhospital outcome of coronavirus disease 2019 (COVID-19) infection Efficacy of Lopinavir/Ritonavir compared with standard care for treatment of coronavirus disease 2019 (COVID-19): a systematic review Cytokine storm and colchicine potential role in fighting SARS-CoV-2 pneumonia Quality assessment of observational studies in a drug-safety systematic review, comparison of two tools: the Newcastle-Ottawa Scale and the RTI item bank RoB 2: a revised tool for assessing risk of bias in randomised trials Colchicine to weather the cytokine storm in hospitalized patients with COVID-19 Effect of colchicine vs standard care on cardiac and inflammatory biomarkers and clinical outcomes in patients hospitalized with coronavirus disease 2019: the GRECCO-19 randomized clinical trial Beneficial effects of colchicine for moderate to severe COVID-19: an interim analysis of a randomized, double-blinded, placebo controlled clinical trial. medRxiv Clinical outcome of patients with COVID-19 pneumonia treated with corticosteroids and colchicine in Colombia Atorvastatin associated with decreased hazard for death in COVID-19 patients admitted to an ICU: a retrospective cohort study A case control study to evaluate the impact of colchicine on patients admitted to the hospital with moderate to severe COVID-19 infection Association between treatment with colchicine and improved survival in a single-centre cohort of adult hospitalised patients with COVID-19 pneumonia and acute respiratory distress syndrome Efficacy of colchicine in non-hospitalized patients with COVID-19. medRxiv Treating COVID-19 with colchicine in community healthcare setting Colchicine treatment in community healthcare setting to prevent severe COVID-19 Colchicine in COVID-19: an old drug, new use Predictive values of neutrophil-tolymphocyte ratio on disease severity and mortality in COVID-19 patients: a systematic review and meta-analysis The rationale for the use of colchicine in COVID-19: comments on the letter by Cumhur Cure M et al Anti-inflammatory therapy for COVID-19 infection: the case for colchicine Interleukin-6 blockade with sarilumab in severe COVID-19 pneumonia with systemic hyperinflammation: an open-label cohort study Colchicine treatment can improve outcomes of coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis